Home > Neurology > EAN 2019 > Parkinson's Disease and other Movement Disorders > No disease-modifying effect of levodopa/carbidopa in Parkinson’s

No disease-modifying effect of levodopa/carbidopa in Parkinson’s

Conference
EAN 2019
Determining disease-modifying qualities of levodopa could result in a rationale for initiating treatment earlier in the course of PD. In a double-blind, placebo-controlled, delayed-start trial, treatment with levodopa/carbidopa had no disease-modifying effect over the course of 80 weeks in patients with early PD [1,2]. In patients without overt disability in daily activities, early start with levodopa improved disease-related quality of life. These were the results of a Dutch multicentre study designed to see if levodopa/carbidopa can slow disease progression in the early phase of the disease. A total of 445 patients with early PD were randomised to levodopa/carbidopa 100/25 mg three times a day for 80 weeks (early-start group), or placebo for 40 weeks followed by levodopa/carbidopa for 40 weeks (delayed-start group). The primary outcome was the mean change in the total score on the Unified Parkinson’s Disease Rating Scale (UPDRS) at week 80. This change w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on